Abstract
Purpose :
To analyse the registration, invitation, consent to programme and successful final outcome of diabetic retinopathy screening offered to all diabetic patients on a national basis.
Methods :
A retrospective review of round 3 (2016) and round 4 (2017) of the Irish Diabetic RetinaScreen (DRS) programme. The retinopathy and maculopathy (R and M) grading system was employed. There is a single electronic patient management system in place (Optomize) to cover screening and treatment arms of the programme. Screening results were analysed and are reported here.
Results :
Growth of the national register is ongoing and now contains 184,000 patients. The eligible cohort (for attendance at screening) is now 162,438 (58% male; 42% female).
Overall, 61.3% (95,042 of 155,060) of the eligible cohort had a screen and final grade in 2016. This increased to 62.2% (100,961 of 162,438) in 2017. Uptake has increased year on year since the programme began.
There are 11,290 in our treatment centres thus overall coverage by DRS is 69.1%.
In 2017 no retinopathy (R0) was detected in 71,614 (70.9%), background retinopathy (R1) in 24,258 (24.0%).
Pre-proliferative (R2) retinopathy was detected in 633 (0.6%). Proliferative retinopathy (R3) was detected in 866 (0.9%).
Of those patients with referable retinopathy (4645: 4.6%), 3807 (3.8%) were routine and 838 (0.8%) urgent. 3018 (3.0%) of cases had referable non-diabetic eye disease (NDED).
There were 271 (0.3%) un-gradeable cases.
We will present trend data for first 4 rounds of screening.
Conclusions :
This is the updated national record of the extent of diabetic retinal disease in the Irish population. It highlights the changes in uptake, spectrum of disease and referral patterns.
Screening uptake has increased from 62,951 (46.8%) in round 1 (2013/14) to 100,961 (62.2%) in round 4 (2017).
Total referrals have reduced from (13.62% to 7.6%) or (13.2% to 4.6% excluding NDED).
We have referred nearly all prevalent proliferative disease (PDR referrals were 2.87% in round 1 and 0.9% in round 4).
We continue to see high rates of NDED. This data will provide a valuable benchmark to continue to plan and optomize management and therapy. As data from treatment centres is now accessible we can report on activity and clinical outcomes.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.